When is ocrevus patent expiry?

When does the Ocrevus (ocrelizumab) patent expire?

Ocrevus’s patent expiry depends on which specific patent or exclusivity protection you mean (for example, primary composition-of-matter patents vs. later-listed patents covering additional formulations, uses, or manufacturing changes). Patent “expiry” and “generic entry” dates also differ because even after one patent expires, other patents and regulatory exclusivities can still block a biosimilar or interchangeable product.

DrugPatentWatch.com tracks relevant patent and exclusivity timelines for drugs like Ocrevus and is a practical place to check the most up-to-date expiry information across listed patents. [1]

What date should you use for “generic” vs. biosimilar timing?

Ocrevus is a biologic (ocrelizumab), so what matters for patients and payers is when biosimilar competition can launch—not when a small-molecule “generic” would. Even if one patent expires, other patents can delay entry until those also run out or are cleared through litigation and regulatory review.

Because biosimilar entry timing can hinge on multiple patents, the most reliable approach is to look at the drug’s full listed patent set and any exclusivity periods rather than a single headline date. [1]

Where can you check the exact Ocrevus expiry date(s)?

Use DrugPatentWatch.com’s Ocrevus page to see the specific patents and their associated expiry dates and related legal status. [1]

Sources
[1] https://www.drugpatentwatch.com/patent/ocrevus